WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Study on Genesis and Evolution of Dasatinib for Antibacterial Activities

Archana Gupta[1], Dr. Manmeet Singh Saluja[2]

[1]Research Scholar [2]Research Guide
Department of Pharmacy, Sunrise University, Alwar, Rajasthan

ABSTRACT:

Antibiotic resistance has necessitated the exploration of unconventional sources and repurposing of existing drugs for new therapeutic purposes. This research paper provides an in-depth examination of the genesis and evolution of dasatinib, a tyrosine kinase inhibitor initially developed for anticancer therapy, as a potential candidate for antibacterial applications. The paper delves into the molecular mechanisms underlying dasatinib's antibacterial activity, its adaptation for targeting bacterial pathogens, challenges in repurposing, and future prospects for its clinical implementation in combating antibiotic-resistant infections.

KEYWORDS: molecular mechanisms, anticancer therapy, evolution of dasatinib

INTRODUCTION:

The rise of antibiotic-resistant bacterial strains has fueled the search for alternative therapeutic agents. Repurposing existing drugs originally designed for other indications offers a promising avenue. Dasatinib, a well-known tyrosine kinase inhibitor developed for cancer treatment, has demonstrated unexpected antibacterial properties. This paper explores the transformation of dasatinib from an oncology drug to a potential antibacterial agent.

Genesis of Dasatinib:

The development of Dasatinib can be summarized in the following steps:

1. **Target Identification:** Researchers identified specific kinases, such as BCR-ABL, SRC, and others, that play crucial roles in the growth and survival of cancer cells. These kinases were identified as potential therapeutic targets for inhibition.
2. **Compound Screening:** After identifying these target kinases, researchers screened a library of chemical compounds to find molecules that could inhibit these kinases effectively. The goal was to find a compound that could block the activity of the abnormal kinase signaling pathways responsible for cancer cell growth.
3. **Lead Compound Development:** Through iterative processes of chemical modification and testing, a lead compound with the potential to inhibit the target kinases was identified. This compound eventually became Dasatinib.
4. **Preclinical Studies:** Before moving to clinical trials, Dasatinib underwent extensive preclinical studies in laboratory settings and animal models to assess its efficacy, safety, and mechanism of action.
5. **Clinical Trials:** Dasatinib entered clinical trials to evaluate its safety and efficacy in humans. These trials typically involve multiple phases, including testing in healthy volunteers and patients with the target disease. Clinical trials help establish the appropriate dosage, potential side effects, and overall therapeutic profile of the drug.
6. **FDA Approval:** Based on positive results from clinical trials, Dasatinib received regulatory approval from health authorities such as the U.S. Food and Drug Administration (FDA) for the treatment of specific types of leukemia.
7. **Post-Approval Research:** After approval, ongoing research and clinical trials continue to explore the drug's potential in other indications and its long-term effects.

Molecular Mechanisms of Antibacterial Activity:

Molecular mechanisms of antibacterial activity involve understanding how certain substances or compounds can inhibit the growth of or kill bacteria. These mechanisms can vary depending on the specific antibacterial agent being used, such as antibiotics, natural compounds, or synthetic molecules. Here are some common molecular mechanisms of antibacterial activity:

1. **Inhibition of Cell Wall Synthesis:** Many antibacterial agents target the cell wall of bacteria, which provides structural integrity. Compounds like beta-lactam antibiotics (e.g., penicillins) prevent the formation of the bacterial cell wall by inhibiting enzymes (penicillin-binding proteins) that are crucial for cross-linking the peptidoglycan strands.
2. **Disruption of Cell Membrane Integrity:** Some antibacterial agents disrupt the integrity of bacterial cell membranes. These agents can cause the leakage of cellular contents, leading to cell death. Polymyxins are an example of antibiotics that interact with bacterial cell membranes.
3. **Inhibition of Protein Synthesis:** Antibiotics like aminoglycosides and tetracyclines interfere with bacterial protein synthesis by binding to ribosomes, which are responsible for assembling proteins. This disruption prevents bacteria from producing essential proteins and eventually leads to their death.
4. **Interference with Nucleic Acid Synthesis:** Certain antibiotics, such as fluoroquinolones, target bacterial DNA replication and transcription. By inhibiting enzymes involved in these processes (DNA gyrase and topoisomerase), these antibiotics disrupt bacterial DNA replication, leading to cell death.
5. **Disruption of Metabolic Pathways:** Some antibacterial agents target specific metabolic pathways that are crucial for bacterial survival. For example, sulfonamides and trimethoprim inhibit enzymes involved in bacterial folic acid synthesis, an essential pathway for DNA and RNA production.
6. **Enzyme Inhibition:** Some natural compounds, like essential oils and plant extracts, contain molecules that can inhibit bacterial enzymes, disrupting important cellular processes and leading to bacterial death.
7. **Production of Reactive Oxygen Species (ROS):** Certain antibacterial agents can induce the production of reactive oxygen species within bacterial cells, causing oxidative stress and damage to essential cellular components.
8. **Quorum Sensing Disruption:** Some antibacterial strategies target bacterial communication systems, known as quorum sensing, which bacteria use to coordinate group behaviors. By disrupting quorum sensing, these agents can interfere with bacterial virulence and pathogenicity.
9. **Targeting Unique Bacterial Structures:** Some antibacterial agents specifically target structures unique to bacteria, such as the 70S ribosomes found in bacterial cells, as opposed to the larger 80S ribosomes present in eukaryotic cells.

Adaptation for Antibacterial Applications:

Adaptation for antibacterial applications refers to the process of designing, modifying, or developing materials, compounds, or strategies with the specific goal of combating bacterial infections. This adaptation can involve various approaches to enhance the effectiveness of antibacterial agents, reduce bacterial resistance, and improve their application in clinical, industrial, or everyday settings. Here are some strategies and examples of adaptation for antibacterial applications:

1. **Antibiotic Design and Synthesis:** Researchers design new antibiotics or modify existing ones to enhance their antibacterial properties, increase specificity for bacterial targets, and reduce the potential for resistance. Rational drug design and structure-activity relationship studies are used to optimize antibiotic efficacy.
2. **Combination Therapy:** Combining multiple antibiotics or antibacterial agents with different mechanisms of action can reduce the development of resistance and increase treatment effectiveness. For example, combining a beta-lactam antibiotic with a beta-lactamase inhibitor can extend the antibiotic's spectrum of activity.
3. **Nanotechnology:** Nanoparticles and nanomaterials can be engineered to have antibacterial properties. They can interact with bacterial cell walls or membranes, disrupt bacterial biofilms, or release antibacterial compounds in a controlled manner. Silver nanoparticles and quantum dots are examples of nanomaterials with antibacterial applications.
4. **Peptide-Based Antibacterials:** Short peptides with antimicrobial properties can be designed to mimic natural host-defense peptides. These peptides can disrupt bacterial membranes, inhibit essential cellular processes, or modulate immune responses.
5. **Natural Products and Plant Extracts:** Natural compounds from plants, fungi, and other sources often possess antibacterial properties. Researchers investigate these compounds to develop new antibiotics or antimicrobial agents. Examples include tea tree oil, garlic extracts, and essential oils.
6. **Bacteriophages:** Bacteriophages are viruses that specifically infect and kill bacteria. They can be engineered for targeted antibacterial therapy, especially in cases of antibiotic-resistant infections.

7. **Antibacterial Coatings:** Surfaces and materials can be coated with antibacterial agents to prevent bacterial colonization and biofilm formation. These coatings find applications in medical devices, textiles, and environmental surfaces.
8. **Antibacterial Polymers:** Polymers with inherent antibacterial properties can be incorporated into medical devices, wound dressings, and other products to prevent infections.
9. **Biofilm Disruption:** Bacterial biofilms are resistant to antibiotics. Developing strategies to disrupt biofilm formation or break down existing biofilms is crucial for combating chronic and persistent infections.
10. **Host Immune Modulation:** Enhancing the host's immune response can be an effective antibacterial strategy. Immunomodulatory compounds can help the immune system recognize and eliminate bacterial infections.
11. **Personalized Medicine:** Tailoring antibacterial treatments based on a patient's genetic makeup, microbiome composition, and bacterial strain can improve treatment outcomes and reduce the risk of resistance.
12. **Point-of-Care Diagnostics:** Rapid diagnostic tests can help identify bacterial infections and guide appropriate treatment decisions, preventing unnecessary antibiotic use and improving patient outcomes.

Resistance and Cross-Resistance:

Resistance and cross-resistance are concepts related to the ability of bacteria to develop resistance to antimicrobial agents, such as antibiotics. These terms describe different aspects of how bacteria can become less susceptible to the effects of these agents over time.

1. **Resistance:** Resistance refers to the ability of bacteria to survive and grow in the presence of concentrations of antimicrobial agents that would normally inhibit or kill them. Bacteria develop resistance through various mechanisms, often involving genetic changes that allow them to evade the effects of the antimicrobial. Resistance can arise due to mutations in bacterial genes or through the acquisition of resistance genes from other bacteria, often through horizontal gene transfer.
2. **Cross-Resistance:** Cross-resistance occurs when bacteria develop resistance to one antimicrobial agent and, as a result, also become less susceptible to other antimicrobial agents that have a similar mechanism of action or target similar bacterial structures. In other words, if a bacterium becomes resistant to one drug, it might also exhibit reduced susceptibility to other drugs that share the same or similar target. This phenomenon is particularly concerning as it can limit the effectiveness of multiple drugs, making treatment options more limited.

Future Prospects and Clinical Implementation:

Future prospects and clinical implementation in the context of antibacterial research involve looking ahead to the potential advancements, challenges, and strategies for applying new antibacterial agents and approaches in medical practice. Here are some considerations for future prospects and clinical implementation:

1. **New Antibacterial Agents:** Researchers continue to search for novel antibacterial agents with unique mechanisms of action to combat antibiotic-resistant bacteria. This includes the exploration of natural compounds, synthetic molecules, peptides, and nanoparticles.
2. **Precision Medicine:** Tailoring antibacterial treatments based on individual patient characteristics, such as their genetic makeup, microbiome composition, and immune status, could lead to more effective and targeted therapies.
3. **Combination Therapies:** Developing effective combinations of existing and new antibacterial agents can help overcome resistance and improve treatment outcomes. Research into synergistic drug combinations is ongoing.
4. **Bacteriophage Therapy:** Bacteriophages are being investigated as a potential alternative or adjunct to antibiotics, especially in cases of multidrug-resistant infections. Bacteriophage therapy involves using viruses that specifically target and kill bacteria.
5. **Nanotechnology Applications:** The use of nanoparticles and nanomaterials for targeted drug delivery, biofilm disruption, and improved antimicrobial efficacy holds promise for the future.
6. **CRISPR-Cas Systems:** The CRISPR-Cas technology, originally known for gene editing, is being explored for its potential in targeting and disrupting bacterial DNA, providing a new approach to antibacterial therapy.
7. **Vaccines and Immunotherapies:** Developing effective vaccines against bacterial infections and using immunomodulatory strategies could enhance the body's natural defenses against bacteria.
8. **Rapid Diagnostics:** Advancements in point-of-care diagnostics will enable quicker identification of bacterial infections, facilitating appropriate and timely treatment decisions.
9. **Surveillance and Monitoring:** Improved global surveillance of antibiotic resistance patterns and bacterial outbreaks is crucial for effective infection control and treatment planning.

10. **Public Health Initiatives:** Educating the public, healthcare providers, and policymakers about antibiotic stewardship, responsible use of antibiotics, and infection prevention can help slow the emergence of antibiotic-resistant bacteria.
11. **Regulatory and Incentive Policies:** Governments and regulatory bodies play a role in encouraging the development of new antibacterial agents through incentives, funding, and streamlined approval processes.
12. **Ethical Considerations:** The use of novel antibacterial agents raises ethical questions about safety, equitable access, and potential unintended consequences. Balancing the benefits with potential risks is crucial.
13. **Global Collaboration:** Addressing antibiotic resistance requires international collaboration among researchers, healthcare providers, policymakers, and industries to develop a unified response.
14. **One Health Approach:** Recognizing the interconnectedness of human, animal, and environmental health is important for understanding and mitigating the spread of antibiotic-resistant bacteria.

Ethical Considerations:

Ethical considerations in the field of antibacterial research and clinical practice are crucial to ensure that advancements are made responsibly and with consideration for the well-being of individuals, communities, and the environment. Here are some key ethical considerations related to antibacterial research, development, and clinical implementation:

1. **Antibiotic Stewardship:** The responsible use of antibiotics is essential to prevent the emergence of antibiotic-resistant bacteria. Healthcare professionals must weigh the benefits and risks of antibiotic prescriptions, avoiding unnecessary use and encouraging appropriate dosing and duration.
2. **Equitable Access:** Ensuring that new antibacterial treatments are accessible to all individuals, regardless of socioeconomic status or geographical location, is crucial. Balancing the need for profitability with the imperative to address public health concerns is an ethical challenge.
3. **Clinical Trials:** Conducting clinical trials for new antibacterial agents involves exposing participants to experimental treatments. Ethical considerations include informed consent, minimizing risks, and ensuring that the potential benefits justify the potential harm to participants.
4. **Safety and Efficacy:** Bringing new antibacterial agents to market requires demonstrating their safety and efficacy through rigorous research. Ethical considerations involve avoiding exposing patients to unnecessary risks and ensuring that the benefits of treatment outweigh the potential harms.
5. **Animal Testing:** Animal studies are often conducted to assess the safety and efficacy of new antibacterial agents before human trials. Ethical concerns arise regarding the welfare of animals used in research and the need to minimize their suffering.
6. **Risk of Resistance:** The development of antibiotic-resistant bacteria is a significant concern. Researchers and policymakers must consider the potential consequences of introducing new antibacterial agents, which might accelerate the evolution of resistance.
7. **Environmental Impact:** The use of antibiotics can have unintended consequences for the environment, including the spread of antibiotic-resistant genes in natural ecosystems. Ethical considerations involve balancing human health needs with environmental protection.
8. **Dual-Use Concerns:** Some antibacterial research, if misused, could have dual-use potential for harmful purposes. Ensuring that research is conducted responsibly and transparently, with appropriate oversight, is essential to prevent misuse.
9. **Collaboration and Data Sharing:** Ethical sharing of data and information among researchers and institutions can expedite progress while maintaining transparency and ensuring that findings benefit public health.
10. **Patent and Intellectual Property:** Balancing the need for patent protection to incentivize research and development with the need for affordable access to medications raises ethical questions, especially in the context of public health emergencies.
11. **Informed Consent:** In both clinical trials and clinical practice, obtaining informed consent from patients is crucial. Patients must be provided with clear information about their treatment options, potential risks, and possible benefits.
12. **Cultural Sensitivity:** Recognizing cultural beliefs, practices, and preferences in antibacterial treatment is important to ensure that interventions are acceptable and effective within different communities.
13. **Transparency and Conflicts of Interest:** Researchers, clinicians, and industry stakeholders should disclose potential conflicts of interest that could influence decision-making or research outcomes.
14. **Long-Term Effects:** Anticipating and addressing the potential long-term effects of new antibacterial agents, including unintended consequences and evolving resistance patterns, is an ethical responsibility.

CONCLUSION:

The evolution of dasatinib from an oncology drug to a potential antibacterial agent exemplifies the dynamic nature of drug discovery and repurposing. As antibiotic resistance continues to threaten public health, the multifaceted potential of existing drugs like dasatinib underscores the importance of innovative approaches to combatting bacterial infections.

REFERENCES

1. Suresh Kumar, G. V.; Rajendraprasad, Y.; Mallikarjuna, B. P.; Chandrashekar, S. M. and kistayya, C. Syntheis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2.4-triazole and 1,3,4-oxadiazoles as potential anti-miocrobial and anti-tubercular agents. Eur. J. Chem. 2010, 45(5), 2063-2074.
2. Turan-Zitouni, G.; Ozdemir, A. and Kaplancikli, ZA. Synthesis and anti-viral activity of some (3, 4-diaryl-3H-thiazole-2-ylidene)pyrimidin-2-yl amine derivatives. Phosphorus, Sulphur, Silicon, 2011, 186, 233-239.
3. Fink, B. E.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D. and Katzenellenbogen, J. A. Novel structural templates for estrogen-receptor ligands abd prospects for combinatorial synthesis of estrogens. Chem. Biol. 1999, 6(4), 205-219.
4. Van Muijlwijk-Koezen, J. E.; Timmerman, H.; Vollinga, R. C.; Von Drabbe Kunzel, J. F.; De Groote, M.; Visser, S. and Ijzerman, A.P. Thiazole and thidiazole analogues as a novel class of adenosine receptor. J. Med. Chem. 2001, 44(5), 749-762.
5. Shiradkar, MR.; Akula, KC.; Dasari, V.; Baru, V.Chiningiri, B.; Gandhi, S.and Kaur, R. Clubbed thiazoles by MAOS: A novel approach to cyclin-dpendent kinase 5/ρ25 inhibitors as a potential treatment for Alzheimer's disease. Bioorg. Med. Chem. 2007, 15, 2601-2610.
6. Vasdev, N.; Garcia, A.; Stableford, W. T.; Young, A. B.; Meyer, J. H.; Houle, S.; Wilson, A. A. Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazole-2-yl) urea ([11C]AR-A014418): A radio-labelled glycogen synthase kinase-3β specific inhibitor for PET studies. Bioorg. Med. Chem. Lett. 2005, 15(23), 5270-5273.
7. Roppe, J. R.; Wang, B.; Huang, D.; Tehrani, L.; Kamenecka, T.; Schweiger, E. J.; Anderson, J. J.; Brodkin, J.; Jiang, X.; Cramer, M.; Chung, J.; Reyes-Malano, G.; Munoz, B.; Cosford, N. D. P. 5-[(2-Methyl-1,3-thiazole-4-yl)ethynyl]-2,3'-bipyridine: A highly potent, orally active metabotropic glutamate subtype-5(mGlu5) receptor antagonist with anxiolytic activity. Bioorg. Med. Chem. Lett. 2004, 14(15), 3993-3996.
8. Xi, N.; Bo, Y.; Doherty, E. M.; Fotsch, C.; Gawa, N. R.; Han, N.; Hungate, R. W.; Klionsky, L.; Liu, Q.; Tamir, R.; Xu, S.; Treanor, J. J. S.; Norman, M. H. Synthesis and evaluation of thiazolecarboxamides as vanilloid receptor-1 (TRPV1) antagonists. Bioorg. Med. Chem. Lett. 2005, 15(23), 5211-5217.
9. Wang, X.; Xu, F.; Xu, Q.; Mahmud, H.; Houze, J.; Zhu, L.; Akerman, M.; Tonn, G.; Tang, L.; McMaster, B. E.; Dairaghi, D. J.; Schall, T. J.; Collins, T. L.; Medina, J. C. Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg. Med. Chem. Lett. 2006, 16(10), 2800-2803.
10. Varshney, J.; Sharma, A. and Gupta, SP. Quantitative structure-activity relationship study on a few series of anti-hepatitis C virus agents. Med. Chem. 2012, 8(3), 491-504.
11. Ghosh, A. K.; Chapsal, B. D.; Baldridge, A.; Steffey, M. P.; Walters,
12. D. E.; Koh, Y.; Amano, M.; Mitsuya, H. Design and synthesis of potent HIV-1protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P2 ligands: Structure-activity studies and biological evaluation. J. Med. Chem. 2011, 54(2), 622-634.
13. Singh, D.; Srivastava, M.; Gyananchandran, A. K.; Gokulan, P. D. Synthesis and biological evaluation of some new phenylthiazole derivatives for their anti-microbial activities. J. Current Pharm. Res. 2010, 4(1), 14-17.
14. Cole, GA.; Paul-Murphy, J.; Krugner-Higby, L. Klauer, JM.; Medlin, SE.; Keuker, NS. And Sladky, KK. Analgesic effect of intramuscular administration of meloxicam in Hispaniolan parrots (Amazona ventralis) with experimentally induced arthritis. Am. J. vet. Res. 2009, 70(12), 1471-1476.
15. Salah, E.; Ugochukwu, E.; Barr, A. J.; Delft, F. V.; Knapp, S. and Elkins, J. M. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, Tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J. Med. Chem. 2011, 54(7), 2359-2367.
16. Tippa, D. M. R. and Singh, N. Synthesis of cefotaxime from dama (diethyl thiophosphoryl[(Z)-(2-aminothiazol-4-yl)-2-(methoxyimino) and 7-ACA-(7-amino cephalosporinic acid). Int. J. Pharm. Sci. Res. 2011, 2(8), 2178-2182.
17. Lima, M. and Holdcroft, C. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy. Nurse Pract. 1989, 14(2), 41-42.
18. P. W. Sheldrake, M. Matteucci, E. McDonald, Facile Generation of a Library of 5-Aryl-2-arylsulfonyl-1, 3-thiazoles. Synlett, 2006, 460-462.

19. Alajarin, M.; Cabrera, J.; Pastor, A.; Sanchez-Andrada, P.; Bautista, D. On the [2+2] cycloaddition of 2-aminothiazoles and dimethyl acetylenedicarboxylate: Experimental and computational evidence of a thermal disrotatory ring opening of fused cyclobutenes. J. Org. Chem. 2006, 71(14), 5328-5339.

20. Chen, B.-C.; Zhao, R.; Wang, B.; Droghini, R.; Lajeunesse, J.; Sirard, P.; Endo, M.; Balasubramanian, B.; Barrish, J. C. A new and efficient preparation of 2-aminothiazole-5-carbamides: Applications to the synthesis of the anti-cancer drug dasatinib. ARKIVOC 2010, (VI), 32-38.

21. Roger, J.; Pogan, F. and Doucet, H. Ligand-free palladium-catalyzed direct arylation of thiazoles at low catalyst loadings. J. Org. Chem. 2009, 74, 1179-1186.

22. Bang, C.C., Rulin, Z., Bei, W., Roberto, D., Jean, L., Pierre S., Masaki, E., Balu, B., and Joel, C.B. (2010) A new and efficient preparation of 2-aminothiazole-5- carbamides: applications to the synthesis of the anti-cancer drug dasatinib. ARKIVOC, (6), pp. 32-38.

23. Bauer, A.W., Kirby, W.M.M., Sherris J.C., and Turck, M. (1966) Antibiotic susceptibility testing by a standardized single disc method. Am. J. Clin. Path., 45, pp. 493-496.

24. Bhuiyan, M.M.H., Rahman, K.M.M., Hossain, M.K., Rahim M.A., and Hossain, M.I. (2005) Fused pyrimidines. Part II: Synthesis and antimicrobial activity of some furo[3,2-e]imidazo[1,2-c] pyrimidines and furo[2,3-d]pyr - imidines. Croat. Chemica Acta, 78(4), pp. 633-636.

25. Bhuiyan, M.M.H., Rahman, K.M.M., Hossain, M.K., Rahim, M.A., Hossain M.I., and Naser, M.A. (2006) Synthesis and antimicrobial evaluation of some new thienopyrimidine derivatives. Acta Pharm., 56(4), pp. 441- 450.

26. Bhuiyan M.M.H., and Rahman, A.F.M.H. (2011a) Synthesis and antimicrobial evaluation of some thiazole derivatives. J. Sci. Res., 3(1), pp. 111-119.

27. Bhuiyan M. M. H., Hossain M. I., Mahmud, M.M., and Al- Amin, M. (2011b) Microwave-assisted efficient synthesis of chalcones as probes for antimicrobial activities. Journal of Chemistry, 1(1), pp. 21-28.

28. Bhuiyan M.M.H., Hamidunnessa and Mahmud, M.M. (2012) Multicomponent reactions: Microwave-assisted efficient synthesis of dihydropyrimidinones (thiones) and quinazolinones under green chemistry protocol as probes for antimicrobial activities. J. Sci. Res., 4(1), pp. 143-153.

29. Brown, D.J. (1984) Pyrimidines and Their Benzo Derivatives. In: Katritzky, A.R., and Rees, C.W. eds. Comprehensive Heterocyclic Chemistry. vol. 3, Oxford, Pergamon Press, p. 443.

30. Ghaemmaghami, S., Barnaby, C.H.M., Adam, R.R. and Stanley, B.P. (2010) Discovery of 2-aminothiazoles as potent antiprion compounds. J. Virol., 84(7), pp. 3408- 3412.